pH-Sensitive Prodrug Nanoparticles for Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a challenge in developing prodrugs and polymer nanoformulations that balance hydrophobicity for improved encapsulation and controlled release, as highly hydrophobic prodrugs have high loading efficiency but slow release, while less hydrophobic ones have poor loading efficiency and rapid degradation.
Innovation Solution
The development of compounds of Formula (I), which include a biologically active moiety, a pH-sensitive linker, and a hydrophobic moiety, encapsulated in nanoparticles, allowing for controlled release and targeted delivery, particularly to tumor tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the prodrug is highly hydrophobic, then loading efficiency is improved, but rate of release and biodegradation become too slow
Solution Approach 1:
The patent applies parameter changes by systematically varying the hydrophobicity of prodrugs through modification of the R1 group (different alkyl chain lengths: C12, C14, C16, C18) to optimize the balance between loading efficiency and release rate. This allows tuning of the prodrug properties to achieve desired pharmacokinetic behavior.
Solution Approach 2:
The patent uses composite materials by combining the hydrophobic prodrug (with tunable R1 groups) with amphiphilic block copolymers (containing both hydrophobic and hydrophilic blocks) to form core-shell nanoparticles. This composite structure enables high loading efficiency in the hydrophobic core while the hydrophilic shell controls release kinetics and provides stability.
2Quantity of substance
If the prodrug is highly hydrophobic, then loading efficiency is improved, but biodegradation becomes too slow
Solution Approach 1:
The patent applies parameter changes by modifying the hydrophobicity parameters of the prodrug (through different R1 alkyl groups) to achieve optimal balance between loading efficiency and biodegradation rate, preventing excessive accumulation and enabling controlled clearance.
Solution Approach 2:
The amphiphilic block copolymer acts as an intermediary by providing a hydrophilic shell that facilitates interaction with the aqueous biological environment, thereby enhancing the biodegradation and clearance of the otherwise highly hydrophobic prodrug while maintaining high loading efficiency.
3Speed
If a relatively less hydrophobic drug is used, then release and degradation occur at an acceptable rate, but loading efficiency becomes poor
Solution Approach 1:
The patent uses composite materials with a distinct core-shell structure where the hydrophobic core provides high loading capacity and the hydrophilic shell enables controlled release. This allows even less hydrophobic drugs to achieve both acceptable release rates and improved loading efficiency through the protective and organizing effect of the copolymer shell.
4Reliability
If agents are encapsulated into polymer nanoparticles, then drug efficacy is improved and targeted delivery is achieved, but physical properties of drugs limit encapsulation efficiency, loading capacity and stability
Solution Approach 1:
The patent applies parameter changes by systematically modifying the physical-chemical parameters of the prodrugs (hydrophobicity, molecular weight, functional groups) to optimize their compatibility with the nanoparticle system, thereby improving encapsulation efficiency and loading capacity while maintaining targeted delivery efficacy.
Solution Approach 2:
The patent applies local quality by designing prodrugs with specific local chemical features (R1 hydrophobic groups, R2 functional groups) that can interact selectively with different parts of the nanoparticle system, enabling optimized encapsulation in the hydrophobic core while maintaining stability and controlled release through specific interactions with the copolymer shell.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds achieve long circulation times, effective targeting of cancer cells, and reduced side effects by optimizing encapsulation efficiency and release kinetics, leading to improved therapeutic outcomes.
Implementation Method 1
a pH-sensitive linker (Y), wherein Y undergoes pH-dependent hydrolysis
Data Source
AI summary
The disclosure provides compounds of Formula (I), wherein X, Y, and Z are defined herein. The disclosure also provides particles comprising one or more compounds described herein, compositions comprising one or more compounds or particles described herein and a pharmaceutically acceptable carrier, and methods of treating a subject in need thereof comprising administering one or more compounds, particles, or compositions described herein to the subject.X—Y—Z (I).